- -

The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients

RiuNet: Institutional repository of the Polithecnic University of Valencia

Share/Send to

Cited by

Statistics

The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients

Show simple item record

Files in this item

dc.contributor.author Camps, Carlos es_ES
dc.contributor.author Jantus Lewintre, Eloisa es_ES
dc.contributor.author Cabrera, Andrea es_ES
dc.contributor.author Blasco, Ana es_ES
dc.contributor.author Sanmartin, Elena es_ES
dc.contributor.author Gallach, Sandra es_ES
dc.contributor.author Caballero, Cristina es_ES
dc.contributor.author del Pozo, Nieves es_ES
dc.contributor.author Rosell, Rafael es_ES
dc.contributor.author Guijarro, Ricardo es_ES
dc.contributor.author Sirera Pérez, Rafael es_ES
dc.date.accessioned 2017-01-27T13:51:31Z
dc.date.available 2017-01-27T13:51:31Z
dc.date.issued 2011-06
dc.identifier.issn 0169-5002
dc.identifier.uri http://hdl.handle.net/10251/77414
dc.description.abstract Qualitative analysis of circulating DNA in the blood is a promising non-invasive diagnostic and prognostic tool. Our aim was to study the association between the presence of KRAS mutations at codon 12 and several clinical variables in advanced non-small cell lung cancer (NSCLC) patients. Methods: We examined 308 stage IIIB and IV NSCLC patients who were treated with cisplatin and docetaxel. Blood samples were collected before chemotherapy, and circulating DNA was extracted from the plasma using commercial adsorption columns. The KRAS mutational status was determined by an RT-PCR method that is based on allelic discrimination. Results: The median age of the patients was 60 years [31-80], 84% were male, 98% had a performance status of 0-1 and 84% of the patients were in stage IV. The histological subtypes were as follows: 30% squamous cell carcinoma (SCC), 51% adenocarcinoma (ADC) and 19% others. Of the 277 response-evaluated patients, 1% achieved a complete response (CR), 26% achieved a partial response (PR), 34% had stable disease (SD) and 39% had progressive disease (PD). Additionally, 27 (8.8%) patients had KRAS mutations; 26 had a KRAS codon 12 TGT mutation, and 1 had a codon 12 GTT mutation. Plasmatic KRAS mutations were found in patients presenting SCC or ADC. Patients with KRAS mutations in plasma DNA had a median progression free survival (PFS) of 5.77 months [3.39-8.14], whereas for patients with wild-type (wt) KRAS, the PFS was 5.43 months [4.65-6.22] (p = 0.277). The median overall survival (OS) in KRAS-mutated patients was 9.07 months [4.43-13.70] vs 10.03 months [8.80-11.26] in wt patients (p = 0.514). Conclusions: In advanced NSCLC patients, there were no significant differences between patients with or without KRAS mutations in plasma-free DNA with respect to the baseline characteristics, response rates, PFS or OS. © 2010 Elsevier Ireland Ltd. es_ES
dc.description.sponsorship This work was sponsored in part by a grant from the Spanish Society of Medical Oncology (SEOM) and by a grant (RD06/0020/1024) from Red Tematica de Investigacion Cooperativa en Cancer (RTICC), Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation & European Regional Development Fund (ERDF) "Una manera de hacer Europa". None of the funding agencies were involved in the design, data management, data analysis, manuscript preparation and review, or decision to submit. en_EN
dc.language Inglés es_ES
dc.publisher Elsevier es_ES
dc.relation Spanish Society of Medical Oncology (SEOM) es_ES
dc.relation Red Tematica de Investigacion Cooperativa en Cancer (RTICC) RD06/0020/1024 es_ES
dc.relation Instituto de Salud Carlos III (ISCIII) es_ES
dc.relation Spanish Ministry of Science and Innovation es_ES
dc.relation European Regional Development Fund (ERDF) es_ES
dc.relation.ispartof Lung Cancer es_ES
dc.rights Reserva de todos los derechos es_ES
dc.subject KRAS es_ES
dc.subject Molecular markers es_ES
dc.subject Non-small cell lung cancer (NSCLC) es_ES
dc.subject Prognostic factors es_ES
dc.subject Cisplatin es_ES
dc.subject DNA es_ES
dc.subject Docetaxel es_ES
dc.subject Adult es_ES
dc.subject Advanced cancer es_ES
dc.subject Aged es_ES
dc.subject Allele es_ES
dc.subject Article es_ES
dc.subject Blood sampling es_ES
dc.subject Cancer chemotherapy es_ES
dc.subject Cancer patient es_ES
dc.subject Cancer staging es_ES
dc.subject Cancer survival es_ES
dc.subject Codon es_ES
dc.subject Disease course es_ES
dc.subject DNA extraction es_ES
dc.subject Female es_ES
dc.subject Gene mutation es_ES
dc.subject Genetic association es_ES
dc.subject Histopathology es_ES
dc.subject Human es_ES
dc.subject Lung adenocarcinoma es_ES
dc.subject Lung non small cell cancer es_ES
dc.subject Lung squamous cell carcinoma es_ES
dc.subject Major clinical study es_ES
dc.subject Male es_ES
dc.subject Multiple cycle treatment es_ES
dc.subject Oncogene K ras es_ES
dc.subject Overall survival es_ES
dc.subject Plasma es_ES
dc.subject Priority journal es_ES
dc.subject Prognosis es_ES
dc.subject Progression free survival es_ES
dc.subject Reverse transcription polymerase chain reaction es_ES
dc.subject Wild type es_ES
dc.subject Carcinoma, Non-Small-Cell Lung es_ES
dc.subject Disease Progression es_ES
dc.subject DNA Mutational Analysis es_ES
dc.subject Follow-Up Studies es_ES
dc.subject Genetic Association Studies es_ES
dc.subject Humans es_ES
dc.subject Lung Neoplasms es_ES
dc.subject Middle Aged es_ES
dc.subject Mutation es_ES
dc.subject Neoplasm Staging es_ES
dc.subject Predictive Value of Tests es_ES
dc.subject Proto-Oncogene Proteins es_ES
dc.subject Ras Proteins es_ES
dc.subject Survival Analysis es_ES
dc.subject.classification MICROBIOLOGIA es_ES
dc.title The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients es_ES
dc.type Artículo es_ES
dc.identifier.doi 10.1016/j.lungcan.2010.09.005
dc.rights.accessRights Cerrado es_ES
dc.contributor.affiliation Universitat Politècnica de València. Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural - Escola Tècnica Superior d'Enginyeria Agronòmica i del Medi Natural es_ES
dc.description.bibliographicCitation Camps, C.; Jantus Lewintre, E.; Cabrera, A.; Blasco, A.; Sanmartin, E.; Gallach, S.; Caballero, C.... (2011). The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer. 72(3):365-369. doi:10.1016/j.lungcan.2010.09.005 es_ES
dc.description.accrualMethod Senia es_ES
dc.relation.publisherversion https://dx.doi.org/10.1016/j.lungcan.2010.09.005 es_ES
dc.description.upvformatpinicio 365 es_ES
dc.description.upvformatpfin 369 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion es_ES
dc.description.volume 72 es_ES
dc.description.issue 3 es_ES
dc.relation.senia 221290 es_ES


This item appears in the following Collection(s)

Show simple item record